Research shows expanding access to obesity treatments could save thousands of lives annually in the US

A new study led by researchers from Yale School of Public Health and the University of Florida has uncovered the life-saving potential of expanding access to newly developed, highly effective weight-loss medications. According to the findings, providing broader access to these treatments could prevent over 40,000 deaths annually in the United States.

The research sheds light on the urgent need to remove the barriers that are preventing people from accessing these medications, which are crucial for public health efforts to tackle the growing obesity crisis. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 74% of Americans live with overweight, and of these individuals, around 43% meet the criteria for obesity.

The widespread impact of obesity on health is well established. It exacerbates serious medical conditions, including type 2 diabetes, cardiovascular diseases, and certain cancers. Despite the significant health risks, the development and widespread availability of highly effective treatments for obesity have been limited. However, recent breakthroughs in pharmaceuticals, especially with the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists—such as Ozempic and Wegovy—and the newer dual gastric inhibitory polypeptide and GLP-1 (GIP/GLP-1) receptor agonists, such as tirzepatide, have revolutionised the management of obesity. These drugs have shown impressive efficacy in weight loss, both in clinical trials and in real-world usage.

In their study, the researchers sought to quantify the potential impact on mortality if access to these medications were expanded. They analysed mortality risk data across different body mass index (BMI) categories, the prevalence of obesity, and current limitations in access due to the high cost of these drugs and insurance coverage restrictions.

The findings suggest that expanding access to these medications to all eligible individuals in the U.S. could prevent as many as 42,027 deaths annually. Among these, approximately 11,769 lives could be saved in individuals living with type 2 diabetes, who are particularly vulnerable to the health complications associated with obesity. Even under current conditions of limited access, the researchers estimate that around 8,592 lives are being saved each year, primarily among those with private insurance.

A key issue highlighted by the study is the disparity in access to these life-saving medications. Currently, the high cost of these treatments—often exceeding $1,000 per month without insurance—means that many people are unable to afford them. For example, Medicare, one of the largest insurance providers for older adults in the U.S., does not cover these medications for weight loss, leaving many people without access. Similarly, Medicaid coverage varies significantly by state, and private insurance often comes with high deductibles and copayments, further limiting accessibility.

“Expanding access to these medications is not just a matter of improving treatment options but also a crucial public health intervention. Our findings underscore the potential to reduce mortality significantly by addressing financial and coverage barriers,” explained Alison P. Galvani, one of the study’s corresponding authors and the Burnett and Stender Families Professor of Epidemiology (Microbial Diseases) at the Yale School of Public Health.

The study also delved into the regional and socioeconomic impacts of expanded drug access. States with particularly high rates of obesity and diabetes, such as West Virginia, Mississippi, and Oklahoma, could see the greatest benefits. Expanding access to these medications in these regions could lead to the largest per capita reductions in mortality.

However, the researchers caution that several challenges need to be addressed before the full potential of these treatments can be realised. The high price of the medications remains a substantial barrier, and concerns have been raised regarding the pharmaceutical industry’s profit margins. Additionally, supply shortages and manufacturing limitations continue to hinder widespread availability.

“Addressing these challenges requires a multifaceted approach,” noted Dr. Burton H. Singer, PhD, another corresponding author of the study and adjunct professor of mathematics at the Emerging Pathogens Institute at the University of Florida. “We need to ensure that drug prices are more aligned with manufacturing costs and increase production capacity to meet demand. At the same time, we must tackle the insurance and accessibility issues that prevent many people from getting the treatment they need.”

The researchers also examined the role of socioeconomic factors in the effectiveness of expanded drug access. Adjusting their estimates to account for income disparities, they still found that expanding access could save a significant number of lives. The study’s findings indicate that improving access to these treatments could not only reduce the healthcare costs associated with obesity-related conditions but also enhance the overall quality of life for many individuals.

The study, published in the Proceedings of the National Academy of Sciences, highlights the critical importance of improving access to these treatments as part of a comprehensive public health strategy to combat the obesity epidemic.